40% of Claims Miss the Mark

March 5, 2026 Sponsored Content 340B Report Views

Early Lessons from Medicare MFP Effectuation in the 340B Program

SPONSORED CONTENT

RxParadigm’s Tungsten+PLUS technology is a purpose-built, enterprise-grade platform designed to operationalize Medicare Maximum Fair Price (MFP) effectuation and 340B rebate claims adjudication at scale. The platform, which serves as a neutral clearinghouse rather than being controlled by either drug manufacturers or covered entities, delivers end-to-end execution across MFP implementation, claims reconciliation, and documented, good-faith dispute resolution, providing manufacturers, covered entities, and pharmacies with a single, neutral infrastructure to manage compliance, reduce financial exposure, and ensure disciplined execution across the full claim’s lifecycle.

This report provides an early, execution-focused assessment of Medicare Maximum Fair Price (MFP) implementation during the first 30 days following the Inflation Reduction Act’s effective date. January exposed fundamental operational stress points across the 340B ecosystem. Although the 340B Rebate Model Pilot was scheduled to launch on January 1, 2026, its suspension by the U.S. District Court for the District of Maine halted implementation, leaving manufacturers and covered entities to navigate unresolved rebate mechanics, inconsistent data-validation standards, and fragmented operational workflows at scale.

Against this backdrop, the IRA’s Medicare Maximum Fair Price (MFP) provisions took effect as scheduled on January 1, formally establishing MFP requirements for a defined set of Medicare Part D drugs. Implementation proceeded despite unresolved operational and regulatory uncertainty, placing immediate execution pressure on manufacturers, covered entities, and dispensing pharmacies.

RxParadigm’s platform was created to enable disciplined, statutory-aligned execution through a centralized, neutral clearinghouse that enforces data integrity, auditability, and duplicate-discount prevention. The platform operates within existing legal and regulatory frameworks while remaining adaptable as HHS advances its 340B pre-rulemaking process.

To evaluate how manufacturers and covered entities navigated the program’s first month under these evolving conditions, RxParadigm conducted an analysis of MFP effectuation activity across Disproportionate Share Hospital (DSH) and Federally Qualified Health Center (FQHC) outpatient pharmacies operating within the Tungsten+PLUS™ 340B Platform.

Claims Processing Performance: Month One of MFP Effectuation

60% of Claims Processed Correctly

Our analysis shows that 60% of Medicare Maximum Fair Price (MFP) claims were processed correctly during the first month of implementation:

9% of total claims were accurately identified as MFP-eligible and paid in accordance with statutory pricing requirements.
51% were correctly classified as 340B claims and appropriately excluded from MFP payment.

Under statute, manufacturers are required to remit MFP payments to dispensing pharmacies within 21 days of claim submission. During the first month of implementation, manufacturers generally issued refunds within 21–22 days, indicating timely execution of payment obligations despite operational uncertainty.

40% of Claims Processed Incorrectly

Notwithstanding timely payments, 40% of claims were processed incorrectly during January, revealing significant execution and data-alignment gaps:

10% of total claims that qualified for MFP payment were incorrectly rejected after being misidentified as 340B.
- The average dollar value per incorrectly rejected claim was $1,088, creating material financial exposure and cash-flow disruption for pharmacies and covered entities.
30% of total claims experienced duplicate payments, in which manufacturers paid both MFP and 340B pricing on the same transaction.
- The average dollar value per duplicate payment was $398, representing meaningful overpayment exposure for manufacturers.

Lower-cost drugs exhibited the highest incidence of duplicate payments, indicating systemic claim-identification and adjudication weaknesses, rather than pricing anomalies, as the primary driver of early-stage errors.

Key Learnings

Execution Is Proceeding, but Accuracy Is the Limiting Factor
Manufacturers are largely meeting statutory MFP payment timelines; however, only 60% of claims were processed accurately in the first month, underscoring that data integrity and claim identification, not payment speed, represent the primary execution risk.
340B Misidentification Drives Financial and Compliance Exposure
Inaccurate 340B identification is the dominant source of error, resulting in both high-value incorrect claim rejections and systemic manufacturer overpayments, increasing dispute volume, cash-flow disruption, and audit risk across the ecosystem.
Neutral, Execution-Ready Infrastructure Is Now a Governance Requirement
Early evidence of duplicate payments and misaligned reimbursements across FQHCs and DSH hospitals demonstrates that manual or fragmented workflows are no longer sufficient. An AI-enabled, neutral clearinghouse infrastructure is essential to protect manufacturer and 340B covered entity revenue, ensure compliant MFP and 340B execution, and sustain scalable operations as regulatory complexity increases. A clearinghouse that is trusted by all parties is the only effective and fair way to resolve pricing discrepancies in the 340B space.

Conclusion

The first 30 days of Medicare MFP implementation produced critical, real-world insights from this analysis of DSH hospital and FQHCs activity. The findings demonstrate a clear and immediate need for execution-ready infrastructure that prioritizes:

Accurate and defensible 340B claim identification
Reliable de-duplication of claims and payments
End-to-end claims reconciliation supported by documented, good-faith dispute resolution and audit-ready controls

As Medicare MFP effectuation converges with ongoing 340B change, the industry is entering a pivotal period of transformation across pharmacy benefit design, specialty drug management, and program execution. In this evolving environment, a neutral clearinghouse delivers scalable, compliant, and operationally efficient drug-supply-chain execution, reducing financial risk, strengthening data integrity, and enabling trust across a new healthcare ecosystem.